Related Experiment Video
Updated: Aug 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients
Blai Coll1, Gerard Aragonés, Sandra Parra
1Centre de Recerca Biomédica, Reus, Spain.
Abstract:
We tested the security and efficacy of ezetimibe in the treatment of HIV-associated dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 mg/day or fluvastatin 80 mg/day. Patients receiving ezetimibe experienced a statistically significant (P = 0.003) 20% reduction in the concentration of LDL-cholesterol, similar to that observed with fluvastatin (24%, P between groups 0.70). We concluded that ezetimibe monotherapy effectively decreases LDL-cholesterol in HIV-infected patients.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
